Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022


      Wrocław, Poland, July 21, 2022 - Captor Therapeutics S.A. (WSE: CTX), a biopharmaceutical company focused on the development of drugs based on Targeted Protein Degradation (TPD) for the treatment of cancer and autoimmune diseases, today announces that it will attend the 13th Annual Wedbush PacGrow Healthcare Conference, being held in New York on August 9th and 10th, 2022.

      Dr. Tom Shepherd, CEO of Captor, will be participating in a discussion panel webinar entitled “Bullseye – Targeted Oncology – In with the New” at 16:20 (CEST) on Tuesday August 9 as well as holding one-on-one meetings with company and investor attendees. The conference will bring together WedBush's institutional clients and management executives from leading public and private healthcare companies. To request a one-on-one meeting with the Captor Therapeutics management team, please contact us at


      About Captor Therapeutics

      Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.  

      More information on Captor Therapeutics is available at:

      LinkedIn: @CaptorTherapeutics

      Twitter: @CaptorTherapeu1


      For further information, please contact:

      Polish Media and Investor relations:

      Point of View

      Bartosz Sawulski

      +48 694 400 787


      International Investor Relations:

      LifeSci Advisors

      Guillaume van Renterghem

      +41 (0)76 735 01 31